These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 15265243)

  • 21. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure.
    Amin N
    Nephrol Dial Transplant; 2002 Feb; 17(2):340-5. PubMed ID: 11812903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
    Ando R; Naito S; Inagaki Y; Hata T; Ishida Y; Chida Y; Takayama M; Tachibana K; Ohtsuka M; Inoue A
    Ther Apher Dial; 2005 Feb; 9(1):16-23. PubMed ID: 15828901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care.
    Russell R; Brookshire MA; Zekonis M; Moe SM
    Clin Nephrol; 2002 Sep; 58(3):238-43. PubMed ID: 12356195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].
    Hoshino J; Ubara Y; Takaichi K
    Clin Calcium; 2004 May; 14(5):731-7. PubMed ID: 15577034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
    Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
    Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical management of hyperphosphatemia.
    Ritz E
    J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).
    Qunibi WY; Hootkins RE; McDowell LL; Meyer MS; Simon M; Garza RO; Pelham RW; Cleveland MV; Muenz LR; He DY; Nolan CR
    Kidney Int; 2004 May; 65(5):1914-26. PubMed ID: 15086935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Experience with sevelamer in peritoneal dialysis].
    Ortiz A; Ríos F; Melero R; Reyero A; Gazapo R; Casado S
    Nefrologia; 2003; 23(5):432-6. PubMed ID: 14658169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats.
    Katsumata K; Kusano K; Hirata M; Tsunemi K; Nagano N; Burke SK; Fukushima N
    Kidney Int; 2003 Aug; 64(2):441-50. PubMed ID: 12846739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
    Suñer M; Guerrero A; Montes R; Rivera M; Ruiz A; Martínez-García M; Pérez-Valdivia MA; Mateos J
    Nefrologia; 2004; 24(2):142-8. PubMed ID: 15219089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The therapeutic potential of novel phosphate binders.
    Querfeld U
    Pediatr Nephrol; 2005 Mar; 20(3):389-92. PubMed ID: 15650884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial.
    Chertow GM; Dillon MA; Amin N; Burke SK
    J Ren Nutr; 2000 Jul; 10(3):125-32. PubMed ID: 10921533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
    Chertow GM; Burke SK; Raggi P;
    Kidney Int; 2002 Jul; 62(1):245-52. PubMed ID: 12081584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J; Piecha G; Kokot F; Wiecek A
    J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H; Koiwa F; Shishido K; Kinugasa E
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
    Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
    J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients.
    White CA; Jaffey J; Magner P
    Kidney Int; 2007 Feb; 71(4):312-7. PubMed ID: 17183248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different routes bridging calcium in Japanese hemodialysis patients.
    Hamano T; Fujii N; Ito T; Imai E
    Ther Apher Dial; 2005 Feb; 9(1):32-8. PubMed ID: 15828903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.